Cargando…
HIV and HAART-Associated Dyslipidemia
Effective highly active antiretroviral therapy (HAART) for human immunodeficiency virus-1 (HIV) infection has led to marked improvement in life-expectancy for those infected with HIV. Despite reductions in the incidence of AIDS with effective treatment, patients continue to experience considerable m...
Autores principales: | Feeney, Eoin R, Mallon, Patrick W.G |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Bentham Open
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3106351/ https://www.ncbi.nlm.nih.gov/pubmed/21643501 http://dx.doi.org/10.2174/1874192401105010049 |
Ejemplares similares
-
Genetic Markers Associated to Dyslipidemia in HIV-Infected Individuals on HAART
por: Lazzaretti, Rosmeri K., et al.
Publicado: (2013) -
Dyslipidemia and associated risk factors among HIV/AIDS patients on HAART in Asmara, Eritrea
por: Achila, Oliver Okoth, et al.
Publicado: (2022) -
Prevalence and predictors of dyslipidemia among HAART treated and HAART naive HIV positive clients attending Debre Tabor Hospital, Debre Tabor, Ethiopia
por: Tilahun, Anemut, et al.
Publicado: (2022) -
Dyslipidemia and Cardiovascular Disease Risk Factor Management in HIV-1-Infected Subjects Treated with HAART in the Spanish VACH Cohort
por: Domingo, Pere, et al.
Publicado: (2008) -
Is PPARγ a Prospective Player in HIV-1-Associated Bone Disease?
por: Cotter, Eoin J., et al.
Publicado: (2009)